PRX-03140

PRX-03140 is a drug that was developed by Epix Pharmaceuticals for the treatment of Alzheimer's disease. It acts as a 5-HT4 receptor agonist and has been shown to improve cognitive function in animal studies, but it was discontinued in human trials due to lack of efficacy.

History

PRX-03140 was developed by Epix Pharmaceuticals, a company that specializes in the discovery and development of novel pharmaceuticals. The drug was designed to target the 5-HT4 receptor, a type of serotonin receptor that is involved in learning and memory.

Mechanism of Action

PRX-03140 works by stimulating the 5-HT4 receptor. This receptor is found in high concentrations in the brain, particularly in areas involved in learning and memory. By activating this receptor, PRX-03140 is thought to enhance cognitive function.

Clinical Trials

PRX-03140 underwent clinical trials for the treatment of Alzheimer's disease. However, the drug was discontinued in these trials due to lack of efficacy. Despite showing promise in animal studies, PRX-03140 did not demonstrate significant improvement in cognitive function in human patients.

See Also

• Alzheimer's disease
• 5-HT4 receptor
• Epix Pharmaceuticals

References

PRX-03140 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia